IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity-Reference-Cited by-同舟云学术

IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity

Published:2000-04 Issue:4 Volume:42 Page:577-583
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Döpp Rebekka,Schmidt Enno,Chimanovitch Iakov,Leverkus Martin,Bröcker Eva-B.,Zillikens Detlef

Publisher

Elsevier BV

Subject

Dermatology

Reference37 articles.

1. Acquired skin disease of hemidesmosomes;Zillikens;J Dermatol Sci,1999

2. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia;Stanley;Cell,1981

3. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients’ autoantibodies;Stanley;J Clin Invest,1988

4. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera: immunolocalization of this protein to the hemidesmosome;Diaz;J Clin Invest,1990

5. Cloning and primary structural analysis of the bullous pemphigoid autoantigen, BP 180;Giudice;J Invest Dermatol,1992

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omalizumab for the Treatment of Bullous Pemphigoid: A Single Center Experience;OSMANGAZİ JOURNAL OF MEDICINE;2024-07-11

2. I test ELISA potrebbero essere utilizzati al posto del metodo di immunofluorescenza indiretta nella diagnosi delle dermatosi bollose autoimmuni?;La Rivista Italiana della Medicina di Laboratorio;2024-01

3. IgE anti-BP180 NC16A autoantibody in both serum and blister fluid samples does not correlate with disease activity of bullous pemphigoid;European Journal of Dermatology;2023-12

4. A life for autoimmune blistering diseases: in memoriam Detlef Zillikens;Frontiers in Immunology;2023-10-19

5. Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid;Skin Research and Technology;2023-10